INVA - NASDAQ

Innoviva, Inc.

Innoviva, Inc.

INVAยทNASDAQ

$21.70

+0.88%
HealthcareBiotechnology

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.60B
EPS4.0200
P/E Ratio5.40
Earnings Date08/05/2026
Innoviva, Inc.

Innoviva, Inc. Fair Value Envelope

INVA ยท NASDAQ

Our analysis suggests that INVA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $21.7, this represents a potential HIDDEN relative to our calculated worth for Innoviva, Inc..

HIDDEN
Intrinsic Value
Current Price: $21.7

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value$3.9B
+ Cash & Equivalents$550.9M
Firm Value$4.4B
- Debt$269.0M
Equity Value$4.2B
/ Shares Outstanding64,335,319B
DCF Value$65
UNDERVALUED BY 198%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
$204.6M
$212.7M
$221.0M
$229.6M
$238.6M
$248.0M
$257.7M
$267.8M
$278.3M
$289.2M
Maintenance CapEx
-$235.1K
-$244.3K
-$253.8K
-$263.8K
-$274.1K
-$284.8K
-$296.0K
-$307.6K
-$319.6K
-$332.1K
Owner Earnings
$204.4M
$212.4M
$220.7M
$229.4M
$238.4M
$247.7M
$257.4M
$267.5M
$277.9M
$288.8M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
$189.3M
$182.1M
$175.2M
$168.6M
$162.2M
$156.1M
$150.2M
$144.5M
$139.0M
$133.8M
Terminal Value represents 58.7% of Enterprise Value

Related Guides

Blog Categories

Continue your INVA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.